A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Part of paid clinical trials in Orange, California.
- Sponsor
- Avidity Biosciences, Inc.
- Study ID
- NCT07038200
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- FSH Muscular Dystrophy
- FSHD
- FSHD - Facioscapulohumeral Muscular Dystrophy
- FSHD1
- FSHD2
- Facio-Scapulo-Humeral Dystrophy
- Facioscapulohumeral Dystrophy
- Facioscapulohumeral Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy 1
- Facioscapulohumeral Muscular Dystrophy 2
- Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
- Fascioscapulohumeral Muscular Dystrophy
- Fascioscapulohumeral Muscular Dystrophy Type 1
- Fascioscapulohumeral Muscular Dystrophy Type 2
- Landouzy Dejerine Dystrophy
- Landouzy-Dejerine Muscular Dystrophy
- Landouzy-Dejerine Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- AOC-1020 — DRUGPlacebo
- Placebo — DRUGPlacebo will be administered by intravenous (IV) infusion.
Study Details
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Key Dates
- Start date
- Jun 10, 2025
- Status verified
- Sep 2025
- Primary completion
- May 31, 2028
- Completion
- Jul 31, 2028
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: del-braxDel-brax (AOC 1020) will be administered 13 times
- Placebo Comparator: placeboSaline will be administered 13 times
Primary Outcome Measure
Quantitative Muscle Testing (QMT) composite score [ Time Frame: Baseline through Week 78 ]
Central Contacts
- Avidity Biosciences, Inc.858-771-7038
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California Irvine | Orange | California | 92868 | - |
| Stanford University | Palo Alto | California | 94304 | - |
| University of Colorado | Denver | Colorado | 80045 | - |
| University of Florida | Gainesville | Florida | 32608 | - |
| University of Iowa | Iowa City | Iowa | 52242 | - |
| Kansas University Medical Center | Kansas City | Kansas | 66205 | - |
| Kennedy Krieger Institute | Baltimore | Maryland | 21205 | - |
| University of Massachusetts | Worcester | Massachusetts | 01655 | - |
| University of Rochester Medical Center | Rochester | New York | 14642 | - |
| Duke University | Durham | North Carolina | 27708 | - |
| Ohio State University | Columbus | Ohio | 43221 | - |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | - |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | - |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | - |
Find similar trials in Orange, CA
Related Studies
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryRecruiting · University of Rochester · Rochester, New York
- Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)Recruiting · University of Kansas Medical Center · Los Angeles, California
- Biomarker Development for Muscular DystrophiesRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyPHASE1/PHASE2 · Recruiting · Epicrispr Biotechnologies, Inc. · Los Angeles, California